Thursday, 31 July 2014

Could bulk-buying save NHS pounds?


Surgical gloves

Could there be a better deal on gloves?

Would it be better if the NHS bought in bulk?


That’s the question that has arisen since I wrote about how the health service procures essentials like surgical gloves and incontinence pads.


My piece followed the government initiative to publicise the huge variation in prices paid for supplies in different parts of the NHS.


And it has raised a number of questions.


Perhaps the most important is – how could health chiefs do better?


Tens of millions could be wasted by the failure to drive a hard bargain with suppliers.


But getting a better deal for clinical waste disposal bags, surgical gloves and even A4 paper might not be as easy as it looks.


Some take the view that criticism of procurement practices is another example of “NHS bashing” – after all, they argue, the NHS was recently rated as the most efficient healthcare system amongst several leading economies by a major think tanks.


More clout?


Money doctor

It has been suggested millions could be saved by buying in bulk

Others who have worked at various levels of the NHS say they are immensely frustrated by the waste and inefficiency they see day to day.


One leading trust chief executive told me that lecturing health staff on the need to save money resulted in eyes glazing over.


But explaining that every pound saved would be reallocated to front line services and enable better outcomes for patients was an easy message to sell.


Managements, though, clearly have to demonstrate their own competence in cutting costs by better procurement.


Central government – or the top level of NHS England – would have immense clout and buying power.


The idea of Whitehall involvement was dismissed as impractical by some.


However, it’s already happening.


The Department of Health is working with NHS England to negotiate central deals for 100 items.


A list of agreed prices and suppliers will be sent to trusts in the autumn.


If deals for drugs for the NHS can be handled at national level, why not do the same for some other products?


Hidden costs?The Home Office is currently looking at haggling out a central deal for police uniforms with a small group of suppliers.


Police authorities in England would then get the benefit of the lower prices.


The same things is being considered for fire service uniforms – its estimated that £18m could be lopped off an annual budget of £127m.


Centrally negotiated supply contracts will not always be appropriate.



It matters so much because millions of pounds of taxpayers’ money is at stake.”



Regional groups of NHS trusts might pool their procurement to get better prices.


This has been successfully applied in the capital with the NHS London Procurement Partnership (LPP).


Established in 2006, the group says it has saved more than £650m on behalf of members.


One trust is said to be saving nearly £120,000 this year alone on screws used in spinal surgery by getting a deal through LPP rather than trying to negotiate alone with a supplier.


‘Own way best’ mentalitySome health experts are sceptical about centralised procurement.


The former health trust chief Roy Lilley, now a commentator, says because of hidden distribution costs.


He says: “The more you buy the more expensive it is by the time you get to the end user”.


He believes it would easier to tell trusts that non-medical suppliers should never account for more than a set proportion of turnover and let them get on with it.


Those who believe strongly in the merits of smarter procurement acknowledge that applying it in Whitehall is not straightforward.


Alastair McKie, of PA Consulting Group which advises some government departments, says: “It takes a lot of motivated individuals who can share their experiences across different departments to make things happen.”


He says that individual organisations, for example NHS trusts, often believe their way of doing things is best and need a lot convincing to join forces with others.


The NHS supply chain sounds a dry and specialist subject.


But it matters so much because millions of pounds of taxpayers’ money is at stake.


At a time of a squeeze on public funding, the imperative to make better use of that money is as urgent as ever.


Hugh Pym


Article written by Hugh Pym Hugh Pym Health editor




Source BBC News/Health http://www.bbc.co.uk/news/health-28490572


Could bulk-buying save NHS pounds?

Wednesday, 30 July 2014

PMCPA looks to app to simplify the APBI Code of Practice

Code regulator takes ‘digitally-led’ approach in partnership with The Earthworks


Digital pharma marketing blogThe UK’s Code of Practice regulator is turning to digital technology for a strategic communications programme that will see it launch a new app to simplify the ABPI Code next year.


The PMCPA, which administers the Code, will work with Marlow-based agency The Earthworks to create a strategic communications programme that will also include content marketing on the PMCPA’s website and through social media channels.


Vicky Bewer, head of communications at the PMCPA, said: “We are excited about the PMCPA becoming more active in the digital space, with The EarthWorks helping us maximise social media and the quality content we already have.”


The PMCPA has often struggled with its online presence, so anything that can raise its digital game will likely be welcomed by its stakeholders.


Scheduled for a 2015 launch, the PMCPA’s planned iOS app for Apple devices will allow users to navigate and simplify the new Code, with semantic search functionality that displays appropriate commentary and relevant cases.


PMCPA director Heather Simmonds said: “We are really keen to engage with our customers in a more effective way and look forward to doing this in partnership with The EarthWorks.


“The app is a great opportunity to allow users to interrogate the code in a simpler user-friendly way.”


The programme will also see the PMCPA work with other organisations, including online physician community Doctors.net.uk, media agency MSA Media and the PM Society.


There will be a key focus on benchmarking and research to assess perception of the PMCPA amongst their key stakeholders.


Alex Butler, joint managing director at The EarthWorks, said: “I have always associated the PMCPA with upholding the highest standards of ethics and good practice in pharmaceuticals; something definitely not at odds with innovation, but in fact underpinning and supporting best practice.


“We are proud to have been chosen to work with them and believe they will add even greater value to the healthcare community through the development of an exciting new communications strategy over the coming years.”


Through the new partnership The Earthworks will be promoting a strong and positive profile for the PMCPA’s work in relation to the Code and helping build awareness of, and promote, the benefits of self-regulation to the industry, health professionals, patients and the public.


Source PMLive http://www.pmlive.com/blogs/digital_intelligence/archive/2014/july/new_app_will_aim_to_simplify_apbi_code_of_practice




PMCPA looks to app to simplify the APBI Code of Practice

Tuesday, 29 July 2014

ABPI and BIA to support understanding of biosimilars

Trade bodies work together on communication materials for prescribers

ABPI London officesThe two leading UK trade bodies for the life sciences industry have published new materials to help healthcare professionals understand biosimilar medicines.

The Association of the British Pharmaceutical Industry (ABPI) and the Bioindustry Association (BIA) produced the documents in response to the growing importance of biosimilars, which are copies of biological drugs.


For 2013 the global value of biosimilars was over $2.4bn, according to market research specialists Visiongain, while over the next five years they are on track to grow to $23bn, based on an analysis by Frost & Sullivan. This growth is to be driven by the patent expiries of major biological products such as Sanofi’s insulin Lantus, with Lilly and Boehringer Ingelheim partnering on a copy called Abasria.


The ABPI and the BIA said they aimed to address frequently asked questions from healthcare professionals who may not know the full facts about biosimilar medicines.


Highlights include that since 2006, more than 18 branded biosimilar medicines have been granted marketing authorisations in the EU and that biosimilars are expected to enter a much wider range of therapy areas, including rheumatoid arthritis, oncology and diabetes.


The ABPI and the BIA also recommend that all biological medicines, including biosimilar medicines, should be prescribed by brand name and not by the name of the active ingredient – an issue that has caused much debate in the US.


ABPI director of value and access, Paul Catchpole, said: “A number of ABPI and BIA members are developing biosimilar medicines and we are therefore building relationships with key stakeholders to improve understanding of biological medicines, including biosimilar medicines.”


“These new informative materials will assist in ensuring that these medicines are well understood and used appropriately for the benefit of all eligible NHS patients.”


BIA chief executive officer Steve Bates said of the new materials: “We hope that they will assist healthcare professionals in particular to be aware of, and better understand the challenges of, the introduction of biosimilar medicines to the NHS.”


Source PMLive http://www.pmlive.com/pharma_news/abpi_and_bia_to_support_understanding_of_biosimilars_587908




ABPI and BIA to support understanding of biosimilars

Monday, 28 July 2014

Digitally-native HCPs; Key data on the how doctors' use of digital is changing

The way doctors use digital technology is changing, and there will soon be more ‘digitally-native’ healthcare professionals than those who have had to adapt to new technologies.


This infographic compiled by LBi Health and originally published in The Directory contains key details on how doctors are using digital.


Read the LBi Health article ‘Are you talking to digital natives?’


Digitally-native HCPs body


 Source PMLive http://www.pmlive.com/pharma_intelligence/infographic_digitally-native_hcps_544275



Digitally-native HCPs; Key data on the how doctors' use of digital is changing

Friday, 25 July 2014

Antimicrobial resistance priority for new UK science minister

Greg Clark announces collaboration led by Medical Research Council


UK flagThe UK is planning a multi-pronged approach to tackle a growing threat of resistance to antibiotic drugs that is expected to see current treatments become useless within the next two decades.


In his first announcement as science minister Greg Clark said that all seven UK research councils will work together on a strategy to address the many and varied issues related to antimicrobial resistance.


“The united strategy announced today will provide a more coordinated approach to research gathering by bringing together leading cross-industry experts against what is one of today’s greatest scientific problems,” said Clark, who replaced David Willetts in Prime Minister David Cameron’s recent reshuffle.


Led by the Medical Research Council (MRC) the cross-council initiative will apply to medical researchers, biologists, engineers, vets, economists, social scientists, mathematicians and even designers.


According to the MRC, the UK alone has spent £275m on researching the issue since 2007 but “no effective solutions have been found”.


The problems extend beyond antibiotic treatments for diseases – antimicrobial resistance affects livestock infected with bacteria. Little is known about how human and animal resistance is related and the initiative will work to identify common characteristics in both humans and in farm and wild animals in order to find new drugs.


Scientists will also investigate how to track the extent of antimicrobial resistance in different environments, such as the sea, rivers, air, soil and in organisms, as well as in food, homes and hospitals.


In addition to the MRC the collaboration will include the Arts and Humanities Research Council (AHRC), the Biotechnology and Biological Sciences Research Council (BBSRC), the Economic and Social Research Council (ESRC), the Engineering and Physical Sciences Research Council (EPSRC), the Natural Environment Research Council (NERC) and the Science and Technology Facilities Council (STFC).


The announcement follows the recent launch of a UK review into the research environment for companies working in antibiotic development and advise to healthcare professionals to limit the use of antibiotics to curb resistance problems.


Source PMLive http://www.pmlive.com/pharma_news/antimicrobial_resistance_priority_for_new_uk_science_minister_586309




Antimicrobial resistance priority for new UK science minister

Thursday, 24 July 2014

Community pharmacies central to diabetes fight in UK

Risk assessments can help identify people at risk of developing condition

diabetes uk boots risk assessmentConducting risk assessments in community pharmacies can help to identify significant numbers of people at risk of type 2 diabetes in the UK, according to a new report.

The research, conducted by the University of East Anglia with support from Boots UK and Diabetes UK, analysed the outcomes of patients accessing the Diabetes UK Type 2 risk assessment available in Boots UK stores following its launch in January 2013.


According to the report, which was published online in the journal International Journal of Pharmacy Practice, the risk assessments identified that 29 per cent of people who took part were at risk of developing type 2 diabetes in the next decade.


More than 21,000 risk assessments were carried out between the beginning of January 2013 and the end of September 2013, in 1,513 Boots UK pharmacies. The analysis pooled data from 3,513 of these assessments.


Boots UK director of pharmacy Peter Bainbridge commented on the potential for pharmacies to help tackle the growing burden of diabetes for the NHS.


“The research shows the assessments our pharmacy teams perform on a daily basis play an important role in supporting early detection, so patients can take steps to prevent or take control of the condition sooner,” he said.


“As the prevention and management of long term conditions such as diabetes continues to dominate the public health agenda, this research demonstrates the overall value community pharmacy can offer, providing convenient access to healthcare support and reducing the strain on the NHS.”


The importance of accessible diabetes risk assessments was echoed by Dr Richard Brice, chairman of Whitstable Medical Practice.


“All the evidence tells us that the earlier we detect diabetes, the easier and more effective the treatments are. Hence I’m all in favour of easy and accessible, evidence based risk assessment programmes,” he said.


Simon O’Neill, Director of Health Intelligence and Professional Liaison at Diabetes UK, said: “It is great that risk assessments for type 2 diabetes are now available on the high street as it is really important that as many of these people get a risk assessment so that if they are at high risk they can start getting the help they need to reduce their risk, while if they have undiagnosed type 2 they can start getting the support that can help get it under control.


“I would urge people to have their risk assessed if they are overweight, over 40, or over 25 if they are from a South Asian background, or have a close relative with diabetes.”


An online version of the diabetes risk assessment is available on Boots’ website.


The findings fit neatly with the Royal Pharmaceutical Society’s plans for bringing pharmacy centre-stage, as outlined in its Now or Never: shaping pharmacy for the future report, published at the end of last year.


Source PMLive http://www.pmlive.com/pharma_news/community_pharmacies_central_to_diabetes_fight_in_uk_588382




Community pharmacies central to diabetes fight in UK

Wednesday, 23 July 2014

Pharma firms open up drug libraries to UK researchers

AZ, GSK, Janssen, Lilly, Pfizer, Takeda and UCB partner with Medical Research Council

UK flagThe UK’s Medical Research Council (MRC) has stepped up its collaboration with industry via a new agreement that will provide access to compound libraries from seven pharma companies.

The agreement with AstraZeneca (AZ), GlaxoSmithKline (GSK), Janssen R&D, Lilly, Pfizer, Takeda and UCB gives UK researchers access to a ‘virtual library’ of molecules, all of which have undergone some degree of development but are currently lying idle.


Typically, the “deprioritised” compounds failed to show sufficient activity against drug targets but “may still be useful against other diseases with shared biological pathways,” according to the MRC.


The new initiative draws on the experience of an ongoing collaboration between the MRC and AZ, which has involved compound library access since 2011 and was recently expanded to include the establishment of a joint, public-private screening facility at the pharma company’s R&D campus in Cambridge.


The earlier compound-sharing initiative has already shown that academic researchers can find value in projects discontinued by pharma companies and “re-purpose” them for new indications. For example, clinical trials are now underway in Manchester to see whether an AZ drug designed originally to treat gastro-oesophageal reflux disease can be used to treat chronic cough.


Moreover, as the compounds have already undergone preliminary development such as safety testing, any new treatments arising from the research could reach patients more quickly. A full list of available compounds will be published later this year, when UK scientists will be able to apply for MRC funding to use them in academic research projects.


The alliance with AZ has already resulted in £7m-worth ($12m) of funding awarded by the MRC to research projects in the areas of Alzheimer’s, cancer and rare diseases, said Prof Sir John Savill, chief executive of the research organisation.


“By funding studies using these compounds, which otherwise would not be carried out, we will enable scientific breakthroughs that will improve the health of patients in the UK and worldwide,” he added.


The expansion of the initiative is yet another example of a shift towards collaborative R&D in pharma, with drugmakers increasingly trying to forge ties with external researchers.


GSK has taken the approach of running a drug hunter competition, while Janssen’s parent Johnson & Johnson (J&J) has started setting up partnering units in close proximity to biomedical R&D hubs to tap into emerging projects and provide expertise and funding.


Meanwhile, last month the MRC and several UK universities joined with AZ, GSK and J&J – alongside a number of smaller companies – to launch a £16m dementia research programme, which aims to develop ways to detect people at risk of developing dementia as early as possible, improve therapy and ultimately find ways to prevent the disease.


Commenting on the latest announcement, Stephen Whitehead, chief executive of the Association of the British Pharmaceutical Industry (ABPI), said it represents “a fantastic example of open innovation that benefits both industry and academia.”


“The ABPI and our members are committed to greater collaboration with UK researchers and the whole of the academic community to improve our understanding of diseases so that we can continue to develop life-changing medicines for the benefit of patients,” he added.


Source PMLive http://www.pmlive.com/pharma_news/pharma_firms_open_up_drug_libraries_to_uk_researchers_588073




Pharma firms open up drug libraries to UK researchers